对比增强超声与CT/MRI在经动脉化疗栓塞及肝动脉灌注化疗中的比较
本研究纳入2010至2024年间接受TACE或HAIC的患者,以病灶病理完全缓解为参考标准,比较CEUS与CT/MRI评估治疗反应的诊断效能。倾向性评分匹配后,CEUS与CT/MRI的敏感度(96% vs 92%,p=0.07)和特异度(67% vs 57%,p>0.99)均无显著差异;CEUS在HAIC与TACE组间的敏感度(98% vs 94%,p=0.61)和特异度(50% vs 77%,p=0.35)亦无显著差异。结论认为CEUS与CT/MRI在评估HCC对HAIC和TACE治疗反应方面诊断效能无显著差异。
要点
- 以病理完全缓解为参考标准,CEUS与CT/MRI评估HCC治疗反应的敏感度和特异度均无显著差异。
- CEUS在HAIC与TACE两组间的诊断效能(敏感度、特异度)均无显著差异。
- 研究采用1:1倾向性评分匹配以减少TACE与HAIC组间混杂偏倚。
核心结论
- CEUS与CT/MRI在评估HCC对HAIC和TACE治疗反应方面诊断效能无显著差异。
研究设计与样本
- 研究纳入2010年至2024年间接受TACE或HAIC的患者,最终纳入154例患者共167次观察。
- 采用1:1倾向性评分匹配以减少TACE组与HAIC组间的混杂偏倚。
- 以治疗病灶的病理完全缓解为参考标准,比较CEUS与CT/MRI在不同治疗策略下的诊断效能。
诊断标准与关键数值
- 倾向性评分匹配队列中,CEUS与CT/MRI的敏感度为96% vs 92%(p=0.07),特异度为67% vs 57%(p>0.99),均无显著差异。
- CEUS在HAIC组与TACE组间的敏感度为98% vs 94%(p=0.61),特异度为50% vs 77%(p=0.35),均无显著差异。
- 参考标准为治疗病灶的病理完全缓解。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Early assessment of treatment response following locoregional therapy remains a challenge in managing hepatocellular carcinoma (HCC). Recent advancements in contrast-enhanced ultrasound (CEUS) have demonstrated significant potential in the early assessment of tumor viability. This study compared the evaluation capabilities of CEUS and CT/MRI in assessing treatment response to hepatic arterial infusion chemotherapy (HAIC) and transarterial chemoembolization (TACE).
MATERIALS AND METHODS: This study included patients who had received TACE or HAIC between 2010 and 2024. 1:1 propensity score matching was used to reduce confounding bias between the TACE and HAIC groups. A comparative analysis was carried out using pathological complete response of treated lesions as the reference standard to assess the diagnostic performance of CEUS and CT/MRI across different treatment strategies.
RESULTS: A total of 154 patients with 167 observations were ultimately included. In the propensity score matching cohort, CEUS and CT/MRI demonstrated similar diagnostic performance, with no significant differences in sensitivity (96% vs 92%, p = 0.07) or specificity (67% vs 57%, p > 0.99). Additionally, CEUS showed comparable results between HAIC and TACE groups in both sensitivity (98% vs 94%, p = 0.61) and specificity (50% vs 77%, p = 0.35).
CONCLUSION: CEUS demonstrated no significant difference in diagnostic performance compared with CT/MRI in evaluating HCC treatment response to HAIC and TACE.
引用
- Kong W, Qiu L, Li Q, et al. Comparison of Contrast-Enhanced Ultrasound and CT/MRI in Transarterial Chemoembolization and Hepatic Arterial Infusion Chemotherapy. Ultrasound Med Biol. 2025. PMID: 41353068. doi:10.1016/j.ultrasmedbio.2025.11.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。